Fuc2F is a metabolic inhibitor of cellular fucosylation. It is used to investigate the role of fucosylation in biological and pathological processes such as cancer.
Mode of action
Fuc2F is taken-up by mammalian cells and converted into its GDP-Fuc2F derivative inside cells. This is a competitive inhibitor of fucosyltransferase enzymes and induces feedback inhibition of the de novo biosynthesis of fucose. This leads to loss of cell surface fucosylation over time.1
Investigate the role of fucosylation in biological and pathological processes such as cancer. Fuc2F has been used extensively to investigate the role of fucosylation in cancer. Use of Fuc2F in liver and breast cancer cells resulted in reduced proliferation, migration, and downstream growth factor activation.23In vivo studies showed that pre-treatment of HepG2 liver cancer cells reduced outgrowth after subcutaneous transplantation in mice.2 Oral administration of Fuc2F delayed tumor growth of LS174T colorectal carcinoma, breast cancer and A20 lymphoma in mice, likely due to enhanced ADCC after fucose inhibition.45 Oral Fuc2F treatment combined with immunotherapy completely protected against tumor growth due to enhanced ADCC with A20 lymphoma cells, with no apparent toxicity in mice.4
Fuc2F is soluble in a mixture of DMSO and PBS and is added to cell culture from a stock solution.